Display options
Cite
Aurilio G, Cimadamore A, Santoni M, et al. New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?. Cells. 2020;9(6)doi: 10.3390/cells9061522.
Aurilio, G., Cimadamore, A., Santoni, M., Nolè, F., Scarpelli, M., Massari, F., Lopez-Beltran, A., Cheng, L., & Montironi, R. (2020). New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?. Cells, 9(6), . https://doi.org/10.3390/cells9061522
Aurilio, Gaetano, et al. "New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?." Cells vol. 9,6 (2020). doi: https://doi.org/10.3390/cells9061522
Aurilio G, Cimadamore A, Santoni M, Nolè F, Scarpelli M, Massari F, Lopez-Beltran A, Cheng L, Montironi R. New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?. Cells. 2020 Jun 22;9(6). doi: 10.3390/cells9061522. PMID: 32580469; PMCID: PMC7349416.
Copy Download .nbib Format: NLM
Share it on

Cells. 2020 Jun 22;9(6). doi: 10.3390/cells9061522.

New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?.

Cells

Gaetano Aurilio, Alessia Cimadamore, Matteo Santoni, Franco Nolè, Marina Scarpelli, Francesco Massari, Antonio Lopez-Beltran, Liang Cheng, Rodolfo Montironi

Affiliations

  1. Medical Oncology Division of Urogenital and Head and Neck Tumours, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.
  2. Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, United Hospitals, 60126 Ancona, Italy.
  3. Oncology Unit, Macerata Hospital, 62012 Macerata, Italy.
  4. Division of Oncology, S. Orsola-Malpighi Hospital, 40138 Bologna, Italy.
  5. Department of Surgery, Cordoba University Medical School, 14071 Cordoba, Spain.
  6. Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA.

PMID: 32580469 PMCID: PMC7349416 DOI: 10.3390/cells9061522

Abstract

Medical treatment for metastatic castration-resistant prostate cancer (mCRPC) patients has progressively been evolving from a nonspecific clinical approach to genomics-oriented therapies. The scientific community is in fact increasingly focusing on developing DNA damage repair (DDR) defect-driven novel molecules, both as single-agent therapy and in combined treatment strategies. Accordingly, research is under way into combined drug therapies targeting different pathways, e.g. androgen receptor signaling (ARS) and poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) enzymes, immune checkpoint (IC) and PARP, IC, and ARS, and prostate-specific membrane antigen (PSMA). In an attempt to formulate evolving treatment paradigms in mCRPC patients, here we selected clinical research into patients undergoing therapies with emerging molecules, with particular emphasis towards PARP-, IC-, and PSMA-inhibitors. In order to focus on those molecules and drug combinations most likely to be translated into routine clinical care in the near future, we selected only those clinical studies currently recruiting patients. A PubMed search focusing on the keywords "prostate cancer", "metastatic castration-resistant prostate cancer", "DDR pathways", "ARS inhibitors", "PARP inhibitors", "IC inhibitors", "PSMA-targeting agents", and "drug combinations" was performed.

Keywords: ARS inhibitors; DNA damage repair; PARP inhibitors; PSMA-inhibition; drug combinations; immune checkpoint inhibitors; metastatic castration-resistant prostate cancer; prostate cancer

References

  1. Eur Urol. 2018 May;73(5):687-693 - PubMed
  2. Eur Urol. 2017 Jul;72(1):34-42 - PubMed
  3. Oncogene. 2015 May 28;34(22):2815-22 - PubMed
  4. J Clin Oncol. 2019 Feb 20;37(6):490-503 - PubMed
  5. N Engl J Med. 2009 Jul 9;361(2):123-34 - PubMed
  6. J Immunother Cancer. 2018 Dec 4;6(1):141 - PubMed
  7. N Engl J Med. 2011 May 26;364(21):1995-2005 - PubMed
  8. Prostate. 2020 Jan;80(1):99-108 - PubMed
  9. Mutat Res. 2017 Jul;773:174-187 - PubMed
  10. Cancer Chemother Pharmacol. 2019 Dec;84(6):1289-1301 - PubMed
  11. Lancet Oncol. 2020 Jan;21(1):162-174 - PubMed
  12. Science. 2018 Jan 5;359(6371):91-97 - PubMed
  13. Prostate. 2016 Oct;76(14):1257-70 - PubMed
  14. Eur Urol. 2019 Oct;76(4):452-458 - PubMed
  15. J Clin Oncol. 2018 Apr 1;36(10):991-999 - PubMed
  16. Eur Urol. 2018 Aug;74(2):218-225 - PubMed
  17. Nat Commun. 2017 Aug 29;8(1):374 - PubMed
  18. Sci Signal. 2017 May 23;10(480): - PubMed
  19. Cancer Discov. 2018 Apr;8(4):444-457 - PubMed
  20. N Engl J Med. 2015 Jun 25;372(26):2509-20 - PubMed
  21. AJR Am J Roentgenol. 2019 Aug;213(2):275-285 - PubMed
  22. J Biol Chem. 2018 Jul 6;293(27):10524-10535 - PubMed
  23. Clin Cancer Res. 2020 Jun 1;26(11):2487-2496 - PubMed
  24. Nat Genet. 2018 May;50(5):645-651 - PubMed
  25. JAMA Oncol. 2019 Apr 1;5(4):471-478 - PubMed
  26. Prostate. 2020 Apr;80(5):407-411 - PubMed
  27. Cancer Discov. 2012 Dec;2(12):1134-49 - PubMed
  28. Front Oncol. 2018 Dec 21;8:653 - PubMed
  29. N Engl J Med. 2020 May 28;382(22):2091-2102 - PubMed
  30. N Engl J Med. 2012 Sep 27;367(13):1187-97 - PubMed
  31. N Engl J Med. 2015 Oct 29;373(18):1697-708 - PubMed
  32. Curr Oncol Rep. 2019 Mar 27;21(5):42 - PubMed
  33. Science. 2017 Jul 28;357(6349):409-413 - PubMed
  34. N Engl J Med. 2016 Aug 4;375(5):443-53 - PubMed

MeSH terms

Publication Types